Tengion — Investor Presentation (April 2012)
27 slides from Tengion's investor presentation, Apr 17, 2012
Slide 1: Regenerative medicine brought to life
Regenerative medicine brought to life ® April 2012 Exhibit 99.1
Slide 2: Forward-looking Statements
Forward-looking Statements Certain statements in this presentation may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Although Tengion believes that these statements are based upon reasonable assumptions within the bounds of its know
Slide 3: Investment Highlights
Investment Highlights • Biotechnology company focused on tissue and organ regeneration using a patient’s own cells – Strong IP, know-how, and trade secrets around core process • Neo-Urinary Conduit TM : our goal is to improve upon standard of care for bladder cancer patients requiring cystectomy – C
Slide 4: Delivering Organ Regeneration
Delivering Organ Regeneration Novel technology platform that: • Utilizes selected populations of regenerative cells • Harness these cells to create specific neo-organs • Has the potential to produce these neo-organs on a commercial scale
Slide 5: Anticipated Benefits of Our Regenerative Medicine Platform
Anticipated Benefits of Our Regenerative Medicine Platform • Regenerate native-like function and structure • Reduce healthcare costs for organ failure while improving medical outcomes – Avoid the risk of organ rejection – Eliminate the burden and costs of immunosuppression • Provide meaningful clini
Slide 6: Neo-Urinary Conduit
Neo-Urinary Conduit
Slide 7: Neo-Urinary Conduit: Established Medical Need
Neo-Urinary Conduit: Established Medical Need Estimated Urinary Diversion Surgical Procedures Per Year 11,000 13,100
Slide 8: Tengion's Neo-Urinary Conduit
Tengion’s Neo-Urinary Conduit • Regenerates native-like urinary tissue with no bowel resection or urine absorption-related metabolic disorders • Designed to eliminate side effects from use of bowel • Created using patient’s own cells – Cells obtained from simple fat biopsy – Cells grown and placed o
Slide 9: Neo-Urinary Conduit vs. Standard of Care
Neo-Urinary Conduit vs. Standard of Care Non-Continent Urinary Diversion Conduit Neo-Urinary Conduit
Slide 10: Our Neo-Urinary Conduit Offers Advantages
Our Neo-Urinary Conduit Offers Advantages • Potentially shorter, less complex and standardized surgical procedure • Improved recovery times • Avoids side effects associated with bowel tissue resection and urine absorption ₋ Infection ₋ Excess mucus formation ₋ Cancer
Slide 11: Phase Trial Overview
Phase 1 Trial Overview • Open label study to define surgical procedure and safety • Primary efficacy assessment: Structural integrity and conduit patency at 1 year post implant • Will enroll up to 10 patients with primary bladder cancer requiring cystectomy • Expect to complete enrollment by the end
Slide 12: Phase Trial Progress: Translation and Regeneration
Phase 1 Trial Progress: Translation and Regeneration • Four of 10 patients enrolled so far • Results from patients 1-3 provided a framework for an updated procedure for the fourth patient – Ureteral attachment utilizes a widely accepted procedure – Modified stoma ostomy to improve stoma patency – Va
Slide 13: Next Steps for the Neo-Urinary Conduit
Next Steps for the Neo-Urinary Conduit • Expect to implant the 10 th patient by the end of 2012 – Anticipate one-year data available for all patients during 4Q 2013 • Begin phase 2/3 clinical trial during 2H 2013 – Randomized, non-blinded 2-arm trial – N = 250-300 (150 NUC vs 100-150 standard of car
Slide 14: Neo-Kidney Augment
Neo-Kidney Augment
Slide 15: Neo-Kidney Augment Market Opportunity
Neo-Kidney Augment Market Opportunity • Intended to delay the need for dialysis or transplantation • An estimated 26 million adults in the United States have Chronic Kidney Disease (CKD) – 100,000 new dialysis patients each year in the US – 350,000 currently on dialysis – 20% annual mortality – $77,
Slide 16: Tengion's Neo-Kidney Augment
Tengion’s Neo-Kidney Augment • Intended to prevent or delay dialysis or kidney transplantation by increasing renal function in patients with advanced CKD – Neo-Kidney Augment may catalyze the regeneration of functional kidney tissue • Utilizes a patient’s own renal cells – Obtained by needle biopsy
Slide 17: Efficient and Scalable Manufacturing Process
Efficient and Scalable Manufacturing Process
Slide 18: Robust Preclinical Data for Neo-Kidney Augment
Robust Preclinical Data for Neo-Kidney Augment • Significant effects in aggressive rodent models of diabetic kidney failure and CKD - results published in top-tier journals – Diabetic kidney failure model • Uncontrolled diabetic, obese, hypertensive rodent model of kidney failure • Slowed kidney dis
Slide 19: Regenerative Cells Improve Kidney Function and Extend Survival
Regenerative Cells Improve Kidney Function and Extend Survival ZSF1 Groups 1-Year Survival Untreated 20% (1/5) OB ZSF1 + NKA 100% (5/5) Renal Cells improve kidney function over time Effects beyond 1 year of age in renal diseased diabetic rat Renal Cells support survival beyond 50% mortality time poi
Slide 20: Human Kidney Tissue Regeneration in Nude Rats
Human Kidney Tissue Regeneration in Nude Rats Human-derived cells prevent renal failure in CKD Nude Rats for 3 months Human-derived cells improve CKD Nude Rat nephron function I-R/G Injury + Human Renal Cells I-R/G Injury Treatment 1 4 12 Weeks Post-Treatment * * * p<0.05 Delayed progression of CKD
Slide 21: Multiple Mechanisms of Action in CKD
Multiple Mechanisms of Action in CKD • Implanted regenerative cells persist for at least 6 months • Regeneration of functional renal tissue - Regenerative and resident cells regenerate, replace and repair renal structures post-implantation • Attenuation of inflammatory and fibrosis pathways - Molecu
Slide 22: Next Steps for Neo-Kidney Augment
Next Steps for Neo-Kidney Augment • Commence GLP studies to support U.S. IND filing in 1H 2013 – 6 month ZSF1 rat study (diabetic kidney failure) – 3 month canine safety study – 6 month repeat dose canine study • Parallel track European approach – Define pathway during 2H 2012 to European First-in-H
Slide 23: Significant IP and Barriers to Entry
Significant IP and Barriers to Entry • Technology protected by issued patent protection plus recent applications pending — 28 U.S. and 97 international patents and patent applications for regeneration of multiple organs and tissues — Core patents cover composition, design and methods of manufacture*
Slide 24: Corporate
Corporate
Slide 25: Financial Overview and Current Stockholders
Financial Overview and Current Stockholders December 31, 2011 Cash and Investments Long-Term Debt Adjusted Net Loss Shares Outstanding * December 31, 2010 $15.3 M $5.0 M $19.1 M 23.7 M $12.0 M $8.6 M $29.6 M 12.4 M Current cash expected to last until September 2012 * Potential for reverse stock spli
Slide 26: Upcoming Milestones
Upcoming Milestones Milestone Expected Complete enrollment of Neo-Urinary conduit phase 1 clinical trial End of 2012 Define European regulatory pathway for Neo-Kidney Augment program 2H 12 IND filing for Neo-Kidney Augment program 1H 13 Initiate phase 2/3 study for Neo- Urinary Conduit 2H 13 Obtain
Slide 27: Investment Highlights
Investment Highlights • Biotechnology company focused on tissue and organ regeneration using a patient’s own cells – Strong IP, know-how, and trade secrets around core process • Neo-Urinary Conduit TM : our goal is to improve upon standard of care for bladder cancer patients requiring cystectomy – C